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Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea
To the Editor: Resistance to all antimicrobial 
agents has developed in some Neisseria gonor-
rhoeae strains. Dual antimicrobial therapy (cef-
triaxone plus azithromycin) is a recommended 
first-line empirical treatment in many coun-
tries.1-3 We describe treatment failure with dual 
therapy in a patient with gonorrhea.
In December 2014, a heterosexual man pre-
sented to a sexual health clinic in the United 
Kingdom with a 2-week history of urogenital 
symptoms (Table 1). Ten days previously, he 
had returned from Japan, where his Japanese 
female partner had been treated for gonorrhea. 
He reported having no other recent sexual 
partners.
N. gonorrhoeae was detected in a urine spec-
imen and pharyngeal swab on nucleic acid 
amplification testing (Abbott RealTime CT/NG 
assay) and in a culture of a urethral specimen. 
All N. gonorrhoeae–positive specimens on nucleic 
acid amplification testing were also confirmed 
as positive with the use of a duplex polymerase-
chain-reaction (PCR) assay targeting the porA 
pseudogene and opa genes. According to the 
local laboratory, testing with the disk-diffusion 
method showed that the N. gonorrhoeae strain 
was resistant to cefuroxime, ciprofloxacin, and 
tetracycline. The patient declined to undergo 
testing for syphilis and human immunodefi-
ciency virus infection.
The patient received one dose of ceftriaxone 
intramuscularly at a dose of 500 mg plus 1 g 
of azithromycin orally.3 At the test of cure on 
day 15, a urine specimen was negative, but a 
pharyngeal swab remained positive for N. gonor-
rhoeae on the identical nucleic acid amplification 
test. The patient reported that he did not have 
sexual contact after treatment, and he did not 
return until day 79, when a pharyngeal swab 
was positive for N. gonorrhoeae on the nucleic acid 
amplification test.
On day 98, N. gonorrhoeae was detected in a 
pharyngeal sample on the nucleic acid amplifi-
cation test and culture. The patient received 
one dose of ceftriaxone at a dose of 1 g intra-
muscularly plus azithromycin at a dose of 2 g 
orally.3 At the test of cure on day 112, the 
pharyngeal specimen was negative (according 
to the nucleic acid amplification test). Initial pre-
treatment specimens were unavailable for fur-
ther analysis.
The N. gonorrhoeae species was verified with 
the use of the Phadebact Monoclonal GC Test 
and matrix-assisted laser desorption ionization–
time of flight mass spectrometry. Antimicrobial 
susceptibility testing with the use of Etest 
showed that the strain was resistant to ceftriax-
one, azithromycin, cefixime, cefotaxime, peni-
cillin, tetracycline, and ciprofloxacin, but it was 
susceptible to spectinomycin. Whole-genome 
sequencing of one isolate with the use of 
 Illumina MiSeq (BioProject accession number 
PRJNA305360) and conventional sequencing iden-
tified N. gonorrhoeae multilocus sequence type 
ST1901 and a new N. gonorrhoeae multiantigen 
sequence type ST12133 in all specimens (the 
isolate and PCR specimens). Resistance determi-
nants,1 mosaic penicillin-binding protein 2 X 
(which decreases ceftriaxone target affinity), 
deletion of one adenine in the mtrR promoter 
(which increases MtrCDE efflux of ceftriaxone 
and azithromycin), and penB (which decreases 
PorB influx of ceftriaxone and azithromycin) 
were detected in all specimens.
The patient was considered to have treatment 
failure because the post-treatment isolate was 
resistant to ceftriaxone and azithromycin, all 
specimens contained resistance determinants 
and identical sequence types, and reinfection 
was deemed to be unlikely. The N. gonorrhoeae 
strain that caused the failure belonged to the 
identical N. gonorrhoeae multiantigen sequence 
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type genogroup as multilocus sequence type 
ST1901, N. gonorrhoeae multiantigen sequence 
type ST6800, which is spreading in Japan and is 
associated with decreased susceptibility to ceph-
alosporins and azithromycin.4,5
In addition, the treatment failure reflected 
difficulties in treating pharyngeal gonorrhea as 
compared with urogenital gonorrhea.1,3 Pharyn-
geal gonorrhea is rare in heterosexual men. 
However, this patient reported no homosexual 
exposure; this highlights the need to test all 
potential sites of infection. A test of cure, part-
ner notification and treatment, and effective 
antimicrobial stewardship and robust surveil-
lance need to be considered so that gonorrhea 
may continue to be a treatable infection.
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